Phillip P. Chan - 08 Aug 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CTSO
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2025, 19:40:26 UTC
Prior SEC filing: 26 Feb 2025
Next SEC filing: 20 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Mariani attorney-in-fact Phillip P. Chan

Key filing fact

Phillip P. Chan filed Form 4 for Cytosorbents Corp (CTSO) on 08 Aug 2025.

Key facts

This page summarizes Phillip P. Chan's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Aug 2025, 19:40.

Change

Previous filing in this sequence was filed on 26 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001442786 Primary reporting owner

Chan Phillip P.

Relationship: Chief Executive Officer, Director
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Peter J. Mariani attorney-in-fact Phillip P. Chan
Signature date: 08 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Award

Transaction value: $0
Shares: +105,600
Change %: +8.3%
Price: $0.000000
Shares after: 1,382,963
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +136,400
Change %
Price: $0.000000
Shares after: 136,400
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 136,400
Exercise price: $1.00
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Footnote F2

Includes: (i) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

Footnote F3

(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof; and

Footnote F4

(continued from footnote 3) (iv) 1,013,363 shares of Common Stock owned by the Reporting Person.

Footnote F5

These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC remarks

Exhibit 24.1 Power of Attorney